Accro Bioscience (Suzhou) Limited

Accro Bioscience Announces First Patient Enrolled in Phase II/III Clinical Trial of Highly Selective TYK2/JAK1 Inhibitor AC-201 for Non-Segmental Vitiligo

Accro Bioscience (Suzhou) Limited ("Accro Bioscience" or "Accro") today announced that its partner's subsidiary, Shanghai Fosun Pharmaceutical…